https://biontechse.gcs-web.com/news...n-emergency-use

MAINZ, GERMANY, and SHANGHAI, CHINA, January 25, 2021 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “Group”; Stock Code: 600196.SH, 02196.HK) today announced that according to the Food and Health Bureau of the Hong Kong Special Administrative Region of the PRC (“Hong Kong”), the COVID-19 vaccine COMIRNATY® (also known as BNT162b2, Chinese product name: 復必泰TM) based on BioNTech’s proprietary mRNA technology has received authorization for emergency use in Hong Kong. The vaccine will be produced in BioNTech’s manufacturing facilities in Germany and supplied to Hong Kong for administration under the Hong Kong SAR Government’s COVID-19 Vaccination Program.


The vaccine will be produced in BioNTech’s manufacturing facilities in Germany
The vaccine will be produced in BioNTech’s manufacturing facilities in Germany
The vaccine will be produced in BioNTech’s manufacturing facilities in Germany